BACKGROUND: Patients with primary sclerosing cholangitis (PSC) may be at higher risk of malignancy after liver transplantation (LT) compared to other LT recipients. We aimed to determine the cumulative incidence of/risk factors for long-term cancer-related mortality in patients with PSC after LT. METHODS: All adult patients underwent LT for PSC without cholangiocarcinoma from 1984 to 2012, with follow-up through June 2015. We estimated cumulative incidence, risk factors, and mortality from de novo malignancies after LT. RESULTS: Two hundred ninety-three patients were identified (mean [SD] age, 47 [12] years; 63.3% males; 2.4% smoking at LT). Over a median of 11.5 years (range, 6.4-18.6 years), 64 patients (21.8%) developed 73 nonskin cancers, including 46 solid-organ cancers (renal, 11; colorectal, 11; prostate, 7; breast, 5; pancreas, 5; ovarian/endometrial/vulvar cancers, 3; and de novo cholangiocarcinoma, 4). Twenty-two patients developed hematologic malignancies (posttransplant lymphoproliferative diseases, 18; Hodgkin disease, 2; and myelodysplastic syndrome, 2). Five patients developed melanoma. The 1-, 5-, 10-, and 20-year cumulative incidences of cancer were 2.1%, 8.6%, 18.7%, and 27%, respectively. Mortality of patients with PSC who developed cancer was higher than that of patients with PSC without cancer (hazard ratio, 2.2; P < 0.01). On multivariate analysis, recipient's age and elevated pre-LT international normalized ratio were associated with increased risk of de novo (nonskin) malignancy. CONCLUSION: The 10-year cumulative risk of cancer after LT for advanced-stage PSC was 18.7%, with posttransplant lymphoproliferative diseases, colorectal cancer, and renal cell cancer being the most common. Post-LT de novo nonskin cancer decreased overall posttransplant survival. Only recipient's age and elevated international normalized ratio at LT were associated with increased nonskin cancer risk.
BACKGROUND:Patients with primary sclerosing cholangitis (PSC) may be at higher risk of malignancy after liver transplantation (LT) compared to other LT recipients. We aimed to determine the cumulative incidence of/risk factors for long-term cancer-related mortality in patients with PSC after LT. METHODS: All adult patients underwent LT for PSC without cholangiocarcinoma from 1984 to 2012, with follow-up through June 2015. We estimated cumulative incidence, risk factors, and mortality from de novo malignancies after LT. RESULTS: Two hundred ninety-three patients were identified (mean [SD] age, 47 [12] years; 63.3% males; 2.4% smoking at LT). Over a median of 11.5 years (range, 6.4-18.6 years), 64 patients (21.8%) developed 73 nonskin cancers, including 46 solid-organ cancers (renal, 11; colorectal, 11; prostate, 7; breast, 5; pancreas, 5; ovarian/endometrial/vulvar cancers, 3; and de novo cholangiocarcinoma, 4). Twenty-two patients developed hematologic malignancies (posttransplant lymphoproliferative diseases, 18; Hodgkin disease, 2; and myelodysplastic syndrome, 2). Five patients developed melanoma. The 1-, 5-, 10-, and 20-year cumulative incidences of cancer were 2.1%, 8.6%, 18.7%, and 27%, respectively. Mortality of patients with PSC who developed cancer was higher than that of patients with PSC without cancer (hazard ratio, 2.2; P < 0.01). On multivariate analysis, recipient's age and elevated pre-LT international normalized ratio were associated with increased risk of de novo (nonskin) malignancy. CONCLUSION: The 10-year cumulative risk of cancer after LT for advanced-stage PSC was 18.7%, with posttransplant lymphoproliferative diseases, colorectal cancer, and renal cell cancer being the most common. Post-LT de novo nonskin cancer decreased overall posttransplant survival. Only recipient's age and elevated international normalized ratio at LT were associated with increased nonskin cancer risk.
Authors: Edmund Q Sanchez; Shigeru Marubashi; Ghapjoong Jung; Marlon F Levy; Robert M Goldstein; Ernesto P Molmenti; Carlos G Fasola; Thomas A Gonwa; Linda W Jennings; Barbara K Brooks; Goran B Klintmalm Journal: Liver Transpl Date: 2002-03 Impact factor: 5.799
Authors: Francis Y Yao; Manjushree Gautam; Caren Palese; Raquel Rebres; Norah Terrault; John P Roberts; Marion G Peters Journal: Clin Transplant Date: 2006 Sep-Oct Impact factor: 2.863
Authors: Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé Journal: J Hepatol Date: 2002-03 Impact factor: 25.083
Authors: G M Ettorre; P Piselli; L Galatioto; M Rendina; F Nudo; D Sforza; L Miglioresi; G Fantola; C Cimaglia; G Vennarecci; G B Vizzini; A Di Leo; M Rossi; G Tisone; F Zamboni; R Santoro; A Agresta; V Puro; D Serraino Journal: Transplant Proc Date: 2013-09 Impact factor: 1.066
Authors: Mohamad A Mouchli; Siddharth Singh; Lisa Boardman; David H Bruining; Amy L Lightner; Charles B Rosen; Julie K Heimbach; Bashar Hasan; John J Poterucha; Kymberly D Watt; Sunanda V Kane; Laura E Raffals; Edward V Loftus Journal: Inflamm Bowel Dis Date: 2018-04-23 Impact factor: 5.325
Authors: Tommaso Maria Manzia; Roberta Angelico; Carlo Gazia; Ilaria Lenci; Martina Milana; Oludamilola T Ademoyero; Domiziana Pedini; Luca Toti; Marco Spada; Giuseppe Tisone; Leonardo Baiocchi Journal: World J Gastroenterol Date: 2019-09-21 Impact factor: 5.742
Authors: Maryam Haider; Anusha Bapatla; Rana Ismail; Ahmed J Chaudhary; Sana Iqbal; Syed M Haider Journal: Int J Med Sci Date: 2022-01-09 Impact factor: 3.738